CD56+ CD7+ Stem Cell Leukemia/Lymphoma with D2-J.DELTA.1 Rearrangement.
-
- YOSHIDA Tetsuya
- The First Department of Internal Medicine, Fukuoka University School of Medicine
-
- KIMURA Nobuhiro
- The First Department of Internal Medicine, Fukuoka University School of Medicine
-
- SAWADA Hitoshi
- The Division of Internal Medicine, Kokura Memorial Hospital
-
- SUEMATSU Eiichi
- The Division of Internal Medicine, Fukuoka Teishin Hospital
-
- NAGANO Mitsuyuki
- The First Department of Internal Medicine, Fukuoka University School of Medicine
-
- AKIYOSHI Tomi
- The First Department of Internal Medicine, Fukuoka University School of Medicine
-
- MOTOMURA Seiji
- The Division of Internal Medicine, Fukuoka Teishin Hospital
-
- KIKUCHI Masahiro
- The First Department of Pathology, Fukuoka University School of Medicine
-
- NISHIMURA Junji
- The Third Department of Internal Medicine, Kyushu University
-
- TAMURA Kazuo
- The First Department of Internal Medicine, Fukuoka University School of Medicine
Bibliographic Information
- Other Title
-
- CD56+CD7+Stem Cell Leukemia/Lymphoma with D2-Jδ1 Rearrangement
- CD56 CD7 Stem Cell Leukemia Lymphoma with D2-J デルタ 1 Rearrangement
Search this article
Abstract
Object We describe the characteristics of three patients with CD56+CD7+ stem cell leukemia/lymphoma. Methods These blasts were analyzed for morphologic, karyotypic, immunophenotypic, and immunogenotypic features using Southern blot and polymerase chain reaction analysis. Materials Peripheral blood, bone marrow aspirates, or biopsied mediastinal tumor specimens of three CD56+CD7+ stem cell leukemia/lymphoma patients were investigated. Results The bone marrow of all patients showed myeloperoxidase (MPO) negative blast cells with basophilic cytoplasm and distinct nucleoli with no azurophilic granules. The blasts of two patients were classified as acute lymphoblastic leukemia (L2). The liver, spleen, and lymph nodes were unaffected in all patients. AH had an aggressive clinical course. The blasts were strongly positive for both CD7 and CD56 but negative for other T-lineage associated antigens, including CD1, CD2, surface membrane CD3, cytoplasmic CD3c (2/2), CD4, CDS and CDS. The additional antigens were recognized as follows: CD19 (1/3 cases) as a B lineage, CD33 (1/3) as a myeloid marker, CD34 (2/3) as a stem cell, CD38 (1/1) and HLA-DR (2/3). When the patients relapsed, the phenotypes changed to blasts positive for CDS, CD10 and CD13 in patient 1, CDS in patient 2, and CD33 in patient 3. MPO, however, remained negative. Cytogenetic analysis showed no common abnormal karyotype. All had a common D2-Jδ1 induced by T-cell specific enhancer. Rearrangement of TCR β and γ genes occurred in patient 2, and IgH and TCR β underwent rearrangement in patient 3. Conclusion Although a more comprehensive case analysis is necessary, these data suggest the possibility that the blasts of the present cases come from a common lymphoid precursor (T, NK, and B cell) or from a NKT precursor as the fourth lymphoid lineage.<br>(Internal Medicine 38: 547-555, 1999)
Journal
-
- Internal Medicine
-
Internal Medicine 38 (7), 547-555, 1999
The Japanese Society of Internal Medicine
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390282679845933568
-
- NII Article ID
- 10005529396
-
- NII Book ID
- AA10827774
-
- COI
- 1:STN:280:DyaK1MzmtFOisQ%3D%3D
-
- ISSN
- 13497235
- 09182918
-
- NDL BIB ID
- 4791803
-
- PubMed
- 10435360
-
- Text Lang
- en
-
- Data Source
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
-
- Abstract License Flag
- Disallowed